1.
EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome
by Seror, Raphaèle
Annals of the rheumatic diseases, 2010-06, Vol.69 (6), p.1103-1109
2.
Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome
by Seror, Raphaèle
Annals of the rheumatic diseases, 2007-03, Vol.66 (3), p.351-357
3.
Cost-effectiveness of rituximab strategies in rheumatoid arthritis
by Seror, Raphaèle
The Lancet (British edition), 2017, Vol.389 (10067), p.365-366
4.
Measure of function in rheumatoid arthritis: individualised or classical scales?
by Seror, R
Annals of the rheumatic diseases, 2010-01, Vol.69 (1), p.97-101
5.
Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial
by Seror, Raphaèle
Annals of the rheumatic diseases, 2014-12, Vol.73 (12), p.2074-2081
6.
Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study
by Mariette, Xavier
Annals of the rheumatic diseases, 2015-03, Vol.74 (3), p.526-531
7.
Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-rep...
by Seror, Raphaèle
Annals of the rheumatic diseases, 2014-12, Vol.75 (2)
8.
Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)
by Seror, Raphaèle
Annals of the Rheumatic Diseases, 2015-05, Vol.74 (5), p.859-866
9.
EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome
by Seror, Raphaèle
Annals of the rheumatic diseases, 2011-06, Vol.70 (6), p.968-972
10.
Individualising the Western Ontario and McMaster Universities osteoarthritis index (WOMAC) function subscale: incorporating patient priorities for improvement to measure functional...
by Seror, R
Annals of the rheumatic diseases, 2008-04, Vol.67 (4), p.494-499
11.
Control treatments in biologics trials of rheumatoid arthritis were often not deemed acceptable in the context of care
by Estellat, Candice
Journal of clinical epidemiology, 2016, Vol.69, p.235-244
12.
Excessive FMS-like tyrosine kinase3-ligand heralds lymphoma in primary sjögren's syndrome
by Pers, Jacques-Olivier
Annals of the rheumatic diseases, 2011-03, Vol.70 (Suppl 2), p.A59-A59
13.
Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease...
by Seror, Raphaèle
Annals of the rheumatic diseases, 2010-12, Vol.69 (12), p.2125-2130
14.
Genetic contribution of DKK-1 polymorphisms to RA structural severity and DKK-1 level of expression
by Miceli-Richard, Corinne
Annals of the Rheumatic Diseases, 2015-07, Vol.74 (7), p.1480-1481
15.
Classification criteria for Sjögren's syndrome: we actually need to definitively resolve the long debate on the issue
by Vitali, Claudio
Annals of the rheumatic diseases, 2013-04, Vol.72 (4), p.476-478
16.
18F-FDG PET/CT of extensive rheumatoid nodulosis
by Roblot, Victoire
European journal of nuclear medicine and molecular imaging, 2017-09-10, Vol.44 (13), p.2333-2334
17.
Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)
by Seror, Raphaèle
Annals of the rheumatic diseases, 2015, Vol.74 (5), p.859
18.
18.sup.F-FDG PET/CT of extensive rheumatoid nodulosis
by Roblot, Victoire
European journal of nuclear medicine and molecular imaging, 2017-12-01, Vol.44 (13), p.2333
19.
18 F-FDG PET/CT of extensive rheumatoid nodulosis
by Roblot, Victoire
European journal of nuclear medicine and molecular imaging, 2017-12, Vol.44 (13), p.2333
20.
Excessive FMS-like tyrosine kinase3-ligand heralds lymphoma in primary sjoegren's syndrome
by Pers, Jacques-Olivier
Annals of the rheumatic diseases, 2011-01-01, Vol.70, p.A59-A59
